 Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands 	1	The impact of the COVID-19 pandemic on hospital services for patients with cardiac diseases: a
4 Authors: 5 Mats de Lange * ¹ , MD 6 Ana Sofia Carvalho * ^{1, 2} , MD 7 Óscar Brito Fernandes ^{2,3} , MSc, MEd 8 Hester Lingsma ² , PhD 9 Nick Klazinga ¹ , MD, PhD 10 Dionne Kringos ¹ , MSc, PhD 11 * Co-first authors 12 * Co-first authors 13 - 14 - 15 ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, 16 Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 17 ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The 18 Netherlands 19 ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, 20 - 21 - 22 - 23 - 24 Address for correspondence: 25 Ana Sofia Carvalho 26 Department of Public Health, 27 - 28 Postbus, 3000 CA Rotterdam <tr< td=""><td>2</td><td>scoping review</td></tr<>	2	scoping review
 Mats de Lange * ¹, MD Ana Sofia Carvalho * ^{1, 2}, MD Óscar Brito Fernandes ^{2,3}, MSc, MEd Hester Lingsma ², PhD Niek Klazinga ¹, MD, PhD Dionne Kringos ¹, MSc, PhD * Co-first authors * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	3	
 Ana Sofia Carvalho * ^{1,2}, MD Óscar Brito Fernandes ^{2,3}, MSc, MEd Hester Lingsma ², PhD Niek Klazinga ¹, MD, PhD Dionne Kringos ¹, MSc, PhD * Co-first authors * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	4	Authors:
 Óscar Brito Fernandes ^{2,3}, MSc, MEd Hester Lingsma ², PhD Niek Klazinga ¹, MD, PhD Dionne Kringos ¹, MSc, PhD ¹ * Co-first authors * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	5	Mats de Lange * ¹ , MD
 Hester Lingsma², PhD Niek Klazinga¹, MD, PhD Dionne Kringos¹, MSc, PhD * Co-first authors * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	6	Ana Sofia Carvalho * ^{1, 2} , MD
 Niek Klazinga¹, MD, PhD Dionne Kringos¹, MSc, PhD * Co-first authors * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	7	Óscar Brito Fernandes ^{2,3} , MSc, MEd
 Dionne Kringos¹, MSc, PhD * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fövám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	8	Hester Lingsma ² , PhD
 * Co-first authors * Co-first authors ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	9	Niek Klazinga ¹ , MD, PhD
 * Co-first authors * Co-first authors * Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands * Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands * Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	10	Dionne Kringos ¹ , MSc, PhD
 ¹³ ¹⁴ ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	11	
 ¹⁴ ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	12	* Co-first authors
 ¹ Department of Public and Occupational Health, Amsterdam Public Health research institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	13	
 Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	14	
 ² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	15	¹ Department of Public and Occupational Health, Amsterdam Public Health research institute,
 Netherlands ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	16	Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
 ³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest, Hungary Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	17	² Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam, The
 Hungary Hungary Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	18	Netherlands
 21 22 23 24 Address for correspondence: 25 Ana Sofia Carvalho 26 Department of Public Health, 27 Erasmus University Medical Center, 28 Postbus, 3000 CA Rotterdam 29 The Netherlands 20 E: asofia.dc@gmail.com 31 T: +351916303458 	19	³ Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, H-1093, Budapest,
 Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	20	Hungary
 Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	21	
 Address for correspondence: Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	22	
 Ana Sofia Carvalho Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	23	
 Department of Public Health, Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	24	Address for correspondence:
 Erasmus University Medical Center, Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	25	Ana Sofia Carvalho
 Postbus, 3000 CA Rotterdam The Netherlands E: asofia.dc@gmail.com T: +351916303458 	26	Department of Public Health,
 The Netherlands E: asofia.dc@gmail.com T: +351916303458 	27	Erasmus University Medical Center,
 30 E: asofia.dc@gmail.com 31 T: +351916303458 	28	Postbus, 3000 CA Rotterdam
31 T: +351916303458	29	The Netherlands
	30	E: asofia.dc@gmail.com
32	31	T: +351916303458
	32	

1 Abstract 2 3 Aim: To assess the impact of the COVID-19 pandemic on hospital care for cardiac patients. 4 Methods and results: Scoping review, including studies with empirical data on changes in the use of 5 health services measured by performance indicators during January - June 2020. Database searches 6 vielded 6277 articles, of which 838 articles met the inclusion criteria during initial screening. After full-7 text screening, 94 articles were considered for data extraction. In total, 1637 indicators were retrieved, 8 showing large variation in the indicators and their definitions. Most of the indicators that provided 9 information on changes in number of admissions (n=118, 88%) signalled a decrease in admissions; 88% 10 (n=15) of the indicators showed patients' delayed presentation and 40% (n=54) showed patients in a 11 worse clinical condition. A reduction in diagnostic and treatment procedures was signalled by 95% 12 (n=18) and 81% (n=64) of the indicators reporting on cardiac procedures, respectively. Length of stay 13 decreased in 58% (n=21) of the indicators and acute coronary syndromes treatment times increased in 14 61% (n=65) of the indicators. Outpatient activity decreased in 94% (n=17) of the indicators related with 15 outpatient care, whereas telehealth utilization increased in 100% (n=6). Outcomes worsened in 40% 16 (n=35) of the indicators, and mortality rates increased in 52% (n=31). 17 **Conclusion:** All phases of the hospital cardiac care pathway were affected. This information could 18 support the planning of care during the ongoing pandemic and in future events. Furthermore, to ensure 19 continuity of care during crises, fostering the use of standardised indicators is paramount.

20

Keywords: 21

- 22 1- Acute coronary syndrome
- 23 2- Cardiovascular disease
- 24 3- Quality of health care
- 4- Quality indicators 25
- 5- Continuity of care 26

1 Introduction

As of 14 November 2021, the virus causing COVID-19 disease, SARS-CoV-2, has infected 253 million people globally and caused 5.1 million deaths (1-3). Governments have implemented many nonpharmaceutical interventions (NPIs) to mitigate the spread of the SARS-CoV-2 virus (4) in tandem with the rollout of vaccination programmes (5).

6 During the pandemic, concerns started to arise that the increasing number of patients diagnosed with 7 COVID-19 would exceed hospital capacity and overwhelm healthcare systems (6). Therefore, in 8 addition to NPIs and vaccination programmes, the use of health resources for non-COVID care was 9 minimized and elective procedures and appointments were postponed (7,8). The World Health 10 Organisation (WHO) has been calling for attention to the impact of COVID-19 on health care services 11 for patients with non-communicable diseases (NCDs) (9), which seems to be severe and involving 12 multiple clinical areas (10-15). A reduction of healthcare utilization for non-COVID conditions and an 13 increase in case severity were already signalled during the first phase of the pandemic (16,17). Medical 14 professionals also drew attention to people avoiding or delaying care out of fear of getting infected 15 (18,19).

16 Cardiac care has often been mentioned as being affected by the COVID-19 pandemic (20,21). According 17 to the WHO, cardiovascular diseases, which include cardiac diseases, are the leading cause of death 18 globally (22). Before the pandemic, a decelerating pace in the improvement of cardiovascular disease 19 mortality was already identified as a major contributor to the slowdown of life expectancy gains in 20 several Organisation for Economic Co-operation and Development (OECD) member countries (23). The 21 continuity of care for patients with cardiac diseases during crisis is a major concern among healthcare 22 providers (20,24), who seek to strengthen referrals and care pathways, and establishing and maintaining 23 novel models of care. Given the burden of cardiac diseases in healthcare systems globally (22,23), 24 attention for the impact of the COVID-19 pandemic on cardiology patients is justified. Previous studies 25 noticed a decrease in patients presenting with (acute) cardiac conditions and mentioned delays in those 26 patients who eventually did present for hospital care (25-27), which could lead to worse clinical 27 outcomes (28).

In a relatively short period, large amounts of scientific evidence have become available on the impact of the pandemic on patients with cardiac diseases in varying countries. This literature is scattered, which makes it difficult to draw conclusions regarding the impact on cardiac care delivery and the use of data to steer health care services delivery improvements during the current pandemic and future public health crises. Hence, reviewing the existing literature and quantifying the magnitude of this impact helps to systematize, synthesize, and consolidate the evidence, and to formulate recommendations for policy and practice.

8 This scoping review is part of a larger project that focuses on performance indicators used for a range 9 of clinical areas during the COVID-19 pandemic. In this study, we aim to assess the impact of the 10 pandemic on hospital care for cardiac patients in OECD countries, focusing on the different phases of 11 the hospital cardiac care pathway (admission, diagnosis, treatment, outpatient care, outcomes).

1 Methods

2

We pursued a scoping review methodology, considering the extensive number of scientific articles, their heterogeneous character, and the lack of a clear and structured overview of the large sums of literature that have become available on the impact of the pandemic on patients with cardiac conditions. A scoping review can be used to examine emerging evidence and give an overview of the literature and studies available on a certain theme (29). We followed the methodological framework developed by Arksey and O'Malley(30), further developed by Levac et al (31), and the PRISMA extension for scoping reviews to report our methodology (32) (Supplementary material S1).

10

11 Search strategy

12 An initial search in MEDLINE database was performed to get an overview of the number of potentially 13 relevant articles for this study. Given the large number of articles, the MEDLINE and Embase databases 14 were selected to search for this scoping review, as we considered them to sufficiently cover the literature 15 related with delivery of health care services. Pilot searches were conducted to identify a list of suitable 16 search terms. A medical research librarian was consulted to improve the search strategy and adapt it to 17 both databases. The final search strategy included the following key terms and synonyms: COVID-19, 18 pandemic, non-communicable disease, chronic disease, performance indicator, healthcare quality, 19 healthcare utilization, healthcare delivery and other closely related terms. The full search strategy for 20 Embase and MEDLINE can be found in Supplementary material S2. The comprehensive search was 21 conducted by the research librarian on 17-03-2021. No limitations were set regarding language or year 22 of publication. Duplicates were removed using EndNote software. Additional articles of relevance were 23 added by hand-searching the reference lists of the included studies.

24

25

1 Study selection

2 The following *inclusion criteria* were set: 1) studies using empirical data on the use of health services; 3 2) studies had to describe health outcomes and/or performance indicators during the COVID-19 4 pandemic; 3) studies that are presented as original journal articles using quantitative or qualitative 5 methods, such as cohort studies, case-control, cross-sectional designs, case reports, systematic reviews, 6 surveys, and meta-analyses. The following *exclusion criteria* were set: 1) non-primary studies (such as 7 editorials and commentaries); 2) prediction models; 3) clinical case reports; and 4) diseases management 8 or health services organization guidelines; 5) studies about the impact on healthcare workers, patients 9 diagnosed with COVID-19, children, or pregnant women; 6) studies primarily performed in non-OECD 10 countries; 7) articles from which only an abstract was available.

11

12 Methods of selection

An initial screening of the retrieved studies based on title and abstract was performed independently by two researchers (ASC, OBF) using Rayyan (https://www.rayyan.ai/). Studies considered relevant after this phase were exported to a spreadsheet to support full-text screening, which was performed independently by three researchers (MdL, ASC, OBF). For this study only articles on cardiac diseases were analysed. The reason for exclusion of articles was recorded at this point. In case of doubt, the other co-authors were consulted, and a decision was made.

19

20 Data extraction and charting


Data extracted from the included articles were collated in a spreadsheet informed by a pilot on 15 studies (Supplementary material S3). Data extraction was performed independently by three researchers (MdL, ASC, OBF). Extracted data included information on generic and methodological aspects of the article (e.g., authors, title, setting), and information about the indicators reported (e.g., indicator title, and data inclusion/exclusion considerations). For every indicator, we identified the trend reported in the articles (increase/decrease/stable).

1 Synthesis of the results

- 2 The indicators and respective trends were categorised and grouped according to different phases of the
- 3 hospital cardiac care pathway by MdL, followed by a review conducted by ASC (Supplementary
- 4 material S4).

1 Results

- 2 Database searches yielded 6277 articles. Of these, 838 articles focusing on non-communicable diseases
- 3 met the inclusion criteria. After full-text screening of 117 articles focused on cardiac hospital care, a
- 4 total of 94 articles were included in this review (Fig. 1). Twenty-three full-text studies were excluded.
- 5





7 Figure 1 - PRISMA flow diagram of the literature search. Abbreviations: OECD - Organisation for Economic Co-operation

```
8 and Development.
```

- 9
- 10

1 General characteristics of the included articles

The included articles reported on 109 different countries (Fig. 2). Eighty-six articles provided information on one country only. Eight articles involved multiple countries, of which seven also included non-OECD countries. Most articles reported on Italy (n = 20, 21%), followed by the United Kingdom (n = 17, 18%), and Germany (n = 14, 15%).

6





Figure 2 - Countries reported on in the included articles (including articles reporting on multiple countries), colour-graded
 according to number of included papers (n=109)

10

11 Most of the studies used a retrospective cohort design (n = 66, 70%), other studies used a prospective 12 cohort (n = 13, 14%), or survey design (n = 12, 13%). The included studies used three different time 13 periods when comparing pandemic versus pre-pandemic indicators. Most studies compared a COVID-14 19 affected period in 2020 to the same period in the previous year (n = 54, 56%). Other studies (n = 34, 15 36%) compared the COVID-19 affected period to a period immediately before. Lastly, a COVID-19 16 affected period was compared to the average of the same period in several previous years (n = 27, 29%).

- 1 Impact of COVID-19 on the hospital cardiac care pathway
- 2
- 3 The indicators were categorised and grouped according to different phases of the hospital cardiac care
- 4 pathway (Fig. 3), to visualise their combined trends.



- 5
- 6 Figure 3 Categorisation of indicators according to different phases of the hospital cardiac care pathway. *Abbreviations:*
- 7 ACS Acute Coronary Syndrome
- 8

9 Admission

10 A total of 287 indicators regarding the 'admission' phase of the hospital cardiac care pathway were

11 identified. These indicators were grouped into three separate categories: 'admission to care', 'delayed

12 presentation', and 'patients' clinical severity at presentation'.

13

14 Admission to care

Regarding numbers of admissions for cardiac diseases to hospital services, 134 indicators were identified from 49 articles (33-81). Most of the indicators concerned patients with acute coronary syndrome (ACS), heart failure, or cardiac arrythmia. Of these indicators, 118 (88%) reported a decrease

in number of admissions, compared to a non-COVID-19 period, 13 indicators (9.7%) reported a stable
 number of admissions, whereas 3 indicators (2.2%) reported an increase in admission numbers.

3

4 Delayed presentation

5 Regarding the patients' timing of presentation to hospital services, 17 indicators were identified from 6 12 articles (43,50,55,68,79,82-88). All the indicators in this category reported on patients with ACS. 7 Most indicators defined delayed presentation as more than twelve hours after symptom onset. Of these 8 indicators, 15 (88%) reported an increase of the number of patients with a delayed presentation to 9 hospital services for cardiac care compared to a non-COVID-19 period. One indicator (5.9%) reported 10 a stable number of patients with a delayed presentation, and one indicator a decrease.

11

12 Patients' clinical severity

Regarding the patients' clinical severity, 136 indicators were identified from 38 articles (34,38,43,44,46,48,50,53,55,57,59,61,66,68-70,73,77,79,81,83,84,87,89-103). Most of the indicators were markers for patients with ACS, such as left ventricular ejection fraction, Killip class or biomarkers at admission. Other indicators reported on heart failure and cardiac surgery. Of these indicators, 54 (40%) reported a worse clinical condition at admission when compared with patients during the COVID-19 period, 72 indicators (53%) reported a stable clinical condition, and 10 indicators (7.4%) reported a better clinical condition.

20

21 Diagnosis

A total of 19 indicators regarding the 'diagnosis' phase of the hospital cardiac care pathway were identified from 11 articles (49,58,61,65,71,79,81,90,104-106). All the indicators reported on the number of diagnostic procedures, including transthoracic and transoesophageal echocardiograms, non-invasive ischemia tests and coronary angiographies. Of these indicators, 18 (95%) reported a decrease during the COVID-19 period. One indicator (5.3%) reported a stable number of diagnostic procedures performed.

1 Treatment

2 A total of 221 indicators regarding the 'treatment' phase of the cardiac care pathway were identified.

3 These indicators were grouped into three separate categories: 'procedure numbers', 'length of stay', and

- 4 'ACS treatment pathway times'.
- 5
- 6 Procedure numbers

Regarding the number of treatment procedures, 79 indicators were identified from 32 articles
(35,37,43,49,50,58-61,64,65,67,71,72,79,84,86-88,90,91,94,97,99,106-113). The indicators collected
mainly concerned the number of percutaneous coronary interventions. Of these indicators, 64 (81%)
reported a decrease in the number of treatment procedures performed during the COVID-19 period, and
15 indicators (19%) reported a stable number of procedures.

12

13 Length of stay

Regarding the patients' in-hospital length of stay, 36 indicators were identified from 25 articles (36,39,46,50,54,55,57,59,61,64,68,75,77,79,81-85,88,94,96,97,111,114). Most of the indicators reported on patients with ACS. Of these indicators, 21 (58%) reported a decrease in the length of stay during the COVID-19 period, 13 indicators (36%) reported a stable length of stay, and 2 indicators (5.6%) reported an increased length of stay.

19

20 Acute Coronary Syndrome treatment pathway times

Regarding the treatment times for ACS care, 106 indicators were identified from 35 articles (34,37,40,43,47,48,55,64,68,70,73,77,79,81-86,89-91,93-98,100-104,114,115). Treatment pathway times reported in the papers were symptom-to-contact, symptom-to-door, symptom-to-diagnosis, symptom-to-balloon (total ischaemia time), contact-to-door, contact-to-balloon, door-to-ECG, door-toballoon, ECG-to-balloon, diagnosis-to-balloon, first medical contact-to-catheter laboratory arrival, catheter-to-puncture, catheter laboratory arrival-to-balloon, puncture-to-balloon, and procedure time. Of these indicators, 65 (61%) reported an increase in ACS treatment pathway times during the COVID-19

1	period, 37 indicators (35%) reported stable treatment pathway times, and 4 indicators (3.8%) reported
2	decreased treatment pathway times.
3	
4	Outpatient care
5	A total of 24 indicators regarding the 'outpatient care' phase of the cardiac care pathway were identified.
6	These indicators were grouped into two separate categories: 'outpatient activity' and 'telehealth'.
7	
8	Outpatient activity volume
9	Regarding outpatient activity, 18 indicators were identified from 8 articles (49,60,62,81,116-119). Most
10	of the indicators concerned only to in-person outpatient activity. Of these indicators, 17 (94%) reported
11	a decrease in outpatient activity volume during the COVID-19 period. One indicator (5.6%) reported a
12	stable number.
13	
14	Telehealth
15	Regarding the use of telehealth, 6 indicators were identified from 6 articles (49,62,116,117,119,120).
16	All the indicators reported an increased use of telehealth.
17	
18	
19	
20	Outcomes
21	A total of 148 indicators regarding the 'outcomes' phase of the cardiac care pathway were identified.
22	These indicators were grouped into two separate categories: 'outcomes and complications' and
23	'mortality rates'.
24	
25	Outcomes and complications
26	Regarding patients' outcomes and complications, 88 indicators were identified from 31 articles

27 (34,37,41,47,50,55,59,66,68,70,71,73,77,82-85,89-93,96,97,100-103,111,112,119). Most indicators

1	were on patients with ACS, in particular ST-elevated myocardial infarctions (STEMI), such as left
2	ventricular ejection fraction at discharge, Thrombolysis in Myocardial Infarction (TIMI) risk score after
3	percutaneous coronary intervention and major adverse cardiovascular events. Of these indicators, 35
4	(40%) reported worse outcomes during the COVID-19 period, 46 indicators (52%) reported a stable
5	outcome, and 7 (8.0%) a better outcome.
6	
7	Mortality rates
8	Regarding mortality rates, 60 indicators were identified from 37 articles (38-41,43,44,46-
9	48,50,54,55,57,59,61,64,66-68,73,75,77,79,81,82,87,92,93,96-99,102,103,111,112,121). The
10	indicators mainly concerned in-hospital mortality or 30-day case mortality rates. Of these indicators, 31
11	(52%) reported an increase in mortality rates during the COVID-19 period, 26 (43%) reported stable
12	mortality rates, and 3 indicators (5%) show decreased mortality rates.
13	
14	An overview of the trends reported by the indicators in each phase of the hospital cardiac care pathway
15	(defined as desirable, undesirable, or stable, following clinical reasoning) is shown in Fig. 4.




Figure 4 - Hospital Cardiac Care Pathway Indicators' Trends during the COVID-19 Pandemic's early stages (Jan-Jun 2020)

1 **Discussion**

2 This study aimed to provide an overview of the impact of the COVID-19 pandemic on hospital services 3 for patients with cardiac diseases. We analysed more than 1600 indicators that were used in 94 papers, 4 reporting on 109 different countries. Our findings show that all phases of the hospital care pathway for 5 patients with cardiac diseases (admission, diagnosis, treatment, outpatient care and outcomes) have 6 been, in different degrees, affected during the pandemic. Admission numbers dropped substantially, and 7 patients arrived later and in a worse clinical condition at the hospital. The number of diagnostic and 8 treatment procedures decreased, ACS treatment pathway times increased, and patients were discharged 9 from the hospital after a shorter length of stay. Outpatient activity decreased, whereas the use of 10 telehealth services increased. Finally, worse clinical outcomes and an increase in mortality rates were 11 reported. These findings can be useful to inform clinicians and policy makers on the main areas affected 12 in the cardiac care pathway, contributing to the monitoring and improvement of health care delivery 13 during the current pandemic and in future unexpected crises. Additionally, these results can be helpful 14 in planning the recovery of care for patients with cardiac diseases.

15 The drop in admissions to hospital services reported in almost all included articles is probably signalling healthcare avoidance, caused by patients afraid of being infected with SARS-CoV-2 in the hospital 16 17 (122). Another explanation could be an actual reduction in the incidence of cardiac diseases during the 18 pandemic. Several explanations have been opted for this reduction in incidence, such as changes in 19 physical activity during lockdowns or a reduction of air pollutants (123-126). Patients with cardiac 20 diseases presenting later to the hospital and arriving in a worse clinical condition than before the pandemic could also have been caused by the fear and avoidance mentioned before, with patients waiting 21 22 for longer periods before seeking care.

Following the drop in admission numbers and decreased outpatient activity, a decrease in the number of diagnostic and treatment procedures were to be expected. On top of patients potentially avoiding care and a possible lower incidence rate of cardiac diseases, elective procedures and surgeries were cancelled (127). These three factors together have likely contributed to reduce procedure volume. The decreased length of hospital stay that we found in most indicators is explained by several authors by a shortage of

hospital bed capacity or the physicians' intention to minimise the risk of patients' exposure to the virus.
For instance, the European Society of Cardiology recommended that patients "should stay in the hospital
for the shortest time possible" (128), and healthcare providers in the United Kingdom were advised to
reduce NSTEMI inpatient stays to 36-48 hours if normal pathways could not be followed (61). The
increased ACS treatment pathway times and the decreased length of stay, together, indicate that the
hospital cardiac care pathway was under pressure during the COVID-19 pandemic and the delivery of
care got squeezed.

The reduction in outpatient care volume we show in this study mostly comes from indicators reporting on in-patient visits. Therefore, it is probably an underestimation of the actual outpatient care provided. The change towards using telehealth shows that innovative measures were taken during the pandemic to avoid the risk of SARS-CoV-2 infection, and health systems adapted quickly to reach out to patients with other means than in-person consultations. In theory, strengthening the use of telehealth to provide continuity of care is beneficial. However, little is known about the quality of care provided and potential inequalities that may have risen from the use of telehealth (e.g., access for all patient groups).

Our findings suggest patients with cardiac conditions are showing worse outcomes and increased mortality rates during the COVID-19 pandemic. The indicators that reported changes on mortality mostly concerned short-term mortality rates (up to 30 days). An even larger impact on mortality might be found when long-term mortality rates will be assessed in later studies. These studies will have to contribute to capturing the real impact that this paper has outlined. The repercussions of care avoidance and cancelled or delayed diagnostic and treatment procedures could reveal itself in the years to come.

To our knowledge, this is the first scoping review that gives an overview of the impact of the COVID-19 pandemic on the hospital cardiac care pathway in OECD countries. The scoping review methodology gives the benefit of mapping the published literature that has come available during the early stages of the COVID-19 pandemic (January - June 2021). However, a scoping review has its limitations. Ideally a systematic review with meta-analyses would be performed. For the articles included in this paper this would be extremely difficult, given their different methodologies, indicators, indicators' definitions, and comparison periods. In fact, the heterogeneity in study characteristics and indicators make it hard to

compare data in a reliable way. In July 2020, the International Training Network for Healthcare Performance Intelligence Professionals (HealthPros) (129) suggested that to compare, manage and improve health systems responsiveness to the pandemic, commonly agreed-upon standardized data and indicators are necessary (130). We recommend devising a uniformly accepted set of indicators with clear definitions to use in future pandemics.

6 Another limitation is that only articles reporting on OECD countries were included in this scoping 7 review. The global repercussions of the COVID-19 pandemic on hospital services for cardiac care will 8 therefore likely be larger than reported in this paper, given the smaller capacity to handle changes in 9 hospital care in low-income countries. On the other hand, publication bias may have played a role in 10 portraying a more severe impact of the pandemic. Physicians might publish sooner when effects of the 11 pandemic are being clearly noticed in their hospital. It could also be the case that the overload with 12 clinical tasks did not allow physicians to find the time to do scientific work, which may counterbalance 13 this limitation. Regardless, we consider our findings to be useful and signalling major trends.

Based on the included articles we are not able to provide an analysis of what exactly caused these changes in the hospital cardiac care pathway. Being able to contextualise these results with future research will be of use for implementing measures to improve care during the current and future pandemics or disasters. We also welcome studies on the quality and access of telemedicine during the COVID-19 pandemic. It would be relevant to study if and how this could improve quality and access of services delivery for the better, also in non-crisis times.

20

21 Conclusion

This study shows that all phases of the hospital care pathway for patients with cardiac diseases were affected during the COVID-19 pandemic. These results signal the hospital services delivery process for cardiac care came under pressure. Lessons should be learnt, and steps taken to be able to safeguard the continuity of care during the ongoing COVID-19 pandemic, and other crises in the future. We call for more research on monitoring and understanding the changes in hospital care. Furthermore, to guide the decisions of health system actors on the implementation of measures to ensure the continuation of

- 1 essential care during future crises, fostering the use of an international standardised set of indicators is
- 2 paramount, making optimal use of existing health information infrastructures.

1 Supplementary data:

- 2 Supplementary material S1 Preferred Reporting Items for Systematic reviews and Meta-Analyses
- 3 extension for Scoping Reviews (PRISMA-ScR) Checklist
- 4 Supplementary material S2 Search strategy
- 5 Supplementary material S3 Data Extraction Form
- 6 Supplementary material S4 Collected and grouped indicators
- 7

8 Figure Legends

- 9 Figure 2 PRISMA flow diagram of the literature search. Abbreviations: OECD Organisation for
- 10 Economic Co-operation and Development. (821 x 876 pixel)
- 11 Figure 2 Countries reported on in the included articles (including articles reporting on multiple
- 12 countries), colour-graded according to number of included papers (n=109) (3915 x 2069 pixel)
- 13 Figure 3 Categorisation of indicators according to different phases of the hospital cardiac care
- 14 pathway. *Abbreviations: ACS Acute Coronary* Syndrome (2113 x 1348 pixel)
- 15 Figure 4 Hospital Cardiac Care Pathway Indicators' Trends during the COVID-19 Pandemic's early
- 16 stages (Jan-Jun 2020) (4409 x 2405 pixel)
- 17

18 Acknowledgements

19 MdL and ASC contributed equally as co-first authors to the development and execution of this study.

20 The authors wish to thank Wichor Bramer from the Erasmus MC Medical Library for developing and

- 21 updating the search strategies used in this study.
- 22

23 Funding

24 This research received no specific grant from any funding agency in the public, commercial, or not-for-

- 25 profit sectors. The participation of ÓBF occurred within a Marie Skłodowska-Curie Innovative Training
- 26 Network (HealthPros Healthcare Performance Intelligence Professionals) that has received funding

- 1 from the European Union's Horizon 2020 research and innovation programme under grant agreement
- 2 Nr. 765141 (https://healthpros-h2020.eu).
- 3
- 4 **Competing interests**
- 5 The authors declare that they have no competing interests.
- 6
- 7 Ethics approval and consent to participate
- 8 Not required.
- 9
- 10 Availability of data and materials
- 11 The data underlying this article are available in Zenodo.org, at
- 12 https://dx.doi.org/10.5281/zenodo.5745755.
- 13

14 Authors' contributions

- 15 All authors contributed to conceptualize the study. ASC, MdL and OBF performed the data collection.
- 16 MdL performed the data analysis with collaboration and revision by ASC. MdL and ASC drafted the
- 17 article. All authors provided feedback and contributed to revising the manuscript. All authors approved
- 18 the final version of the manuscript.

19

1 References

- 2 1. Wu F, Zhao S, Yu B et al. A new coronavirus associated with human respiratory disease in China. *Nature (London)*
- 3 2020;579:265-269.
- 4 <u>https://www.ncbi.nlm.nih.gov/pubmed/32015508</u> 10.1038/s41586-020-2008-3
- 5 2. Johns Hopkins Coronavirus Resource Centre. Johns Hopkins University and Medicine, COVID-19 Map.
- 6 <u>https://coronavirus.jhu.edu/map.html</u> (14-11-2021)
- 7 3. Listings of WHO's response to COVID-19.
- 8 <u>https://www.who.int/news/item/29-06-2020-covidtimeline</u> (28-7-2021)
- 9 4. Haug N, Geyrhofer L, Londei A et al. Ranking the effectiveness of worldwide COVID-19 government interventions.
- 10 *Nature human behaviour* 2020;4:1303-1312.
- 11 <u>https://www.ncbi.nlm.nih.gov/pubmed/33199859</u> 10.1038/s41562-020-01009-0
- 12 5. Understanding Vaccination Progress by Country.
- 13 <u>https://coronavirus.jhu.edu/vaccines/international</u> (27-08-2021)
- 14 6. Moghadas SM, Shoukat A, Fitzpatrick MC et al. Projecting hospital utilization during the COVID-19 outbreaks in the
- 15 United States. Proceedings of the National Academy of Sciences PNAS 2020;117:9122-9126.
- 16 <u>https://www.ncbi.nlm.nih.gov/pubmed/32245814</u> 10.1073/pnas.2004064117
- 17 7. Moletta L, Pierobon ES, Capovilla G et al. International guidelines and recommendations for surgery during Covid-19
- 18 pandemic: A Systematic Review. *International journal of surgery (London, England)* 2020;79:180-188.
- 19 https://dx.doi.org/10.1016/j.ijsu.2020.05.061 10.1016/j.ijsu.2020.05.061
- 20 8. Temporary Emergency Guidance to US Stroke Centers During the Coronavirus Disease 2019 (COVID-19) Pandemic: On
- 21 Behalf of the American Heart Association/American Stroke Association Stroke Council Leadership. *Stroke (1970)*
- 22 2020;51:1910-1912.
- 23 <u>https://www.ncbi.nlm.nih.gov/pubmed/32233972</u> 10.1161/STROKEAHA.120.030023
- 24 9. World Health Organization. NCDs and COVID-19.
- 25 <u>https://www.who.int/teams/noncommunicable-diseases/covid-19</u> (29-7-2021)
- 26 10. Fisher L, Polonsky W, Asuni A, Jolly Y, Hessler D. The early impact of the COVID-19 pandemic on adults with type 1
- 27 or type 2 diabetes: A national cohort study. J Diabetes Complications 2020;34:107748.10.1016/j.jdiacomp.2020.107748

- 1 11. Nakayama A, Takayama N, Kobayashi M et al. Remote cardiac rehabilitation is a good alternative of outpatient cardiac
- 2 rehabilitation in the COVID-19 era. Environ Health Prev Med 2020;25:48.10.1186/s12199-020-00885-2
- 3 12. Nyante SJ, Benefield TS, Kuzmiak CM, Earnhardt K, Pritchard M, Henderson LM. Population-level impact of
- 4 coronavirus disease 2019 on breast cancer screening and diagnostic procedures. Cancer 2021;127:2111-
- 5 2121.10.1002/cncr.33460
- 6 13. Oba A, Stoop TF, Löhr M et al. Global Survey on Pancreatic Surgery During the COVID-19 Pandemic. Ann Surg
- 7 2020;272:e87-e93.10.1097/SLA.000000000004006
- 8 14. Sokolski M, Gajewski P, Zymliński R et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute
- 9 Admissions at the Emergency and Cardiology Departments Across Europe. Am J Med 2021;134:482-
- 10 489.10.1016/j.amjmed.2020.08.043
- 11 15. Weber T, Januszewicz A, Rosei E et al. The corona-virus disease 2019 pandemic compromised routine care for
- 12 hypertension: a survey conducted among excellence centers of the European Society of Hypertension. Journal of
- 13 *hypertension* 2021;39:190-195.
- 14 http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004872-202101000-
- 15 <u>00025</u> 10.1097/HJH.00000000002703
- 16 16. Roy CM, Bollman EB, Carson LM, Northrop AJ, Jackson EF, Moresky RT. Assessing the Indirect Effects of COVID-19
- 17 on Healthcare Delivery, Utilization, and Health Outcomes: A Scoping Review. *European journal of public health*
- 18 2021;31:634-640.
- 19 <u>https://www.ncbi.nlm.nih.gov/pubmed/33755130</u> 10.1093/eurpub/ckab047
- 20 17. Lloyd MR, Stephens SJ, Hong JC et al. The impact of COVID-19 on breast cancer stage at diagnosis. JCO 2021;39:528-
- 21 528.
- 22 <u>https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.528</u> 10.1200/JCO.2021.39.15_suppl.528
- 23 18. Gong K, Xu Z, Cai Z, Chen Y, Wang Z. Internet Hospitals Help Prevent and Control the Epidemic of COVID-19 in
- 24 China: Multicenter User Profiling Study. Journal of medical Internet research 2020;22:e18908.
- 25 <u>https://www.ncbi.nlm.nih.gov/pubmed/32250962</u> 10.2196/18908
- 26 19. Rosenbaum L. The Untold Toll The Pandemic's Effects on Patients without Covid-19. N Engl J Med 2020;382:2368-
- 27 2371.10.1056/NEJMms2009984

- 1 20. Bhatia RT, Gati S, Papadakis M, Sharma S. The Impact of COVID-19 on the Continuity of Cardiovascular Care.
- 2 *European Heart Journal* 2021;42:215-217.
- 3 <u>https://doi.org/10.1093/eurheartj/ehaa742</u> 10.1093/eurheartj/ehaa742
- 4 21. Ball S, Banerjee A, Berry C et al. Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular
- 5 diseases in the UK. *Heart* 2020;106:1890-1897.10.1136/heartjnl-2020-317870
- 6 22. World Health Organization. Factsheet on Cardiovascular diseases (CVDs).
- 7 <u>https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)</u> (16-8-2021)
- 8 23. OECD, The King's Fund. Is Cardiovascular Disease Slowing Improvements in Life Expectancy? 2020;
- 9 24. Kiss P, Carcel C, Hockham C, Peters SAE. The impact of the COVID-19 pandemic on the care and management of
- 10 patients with acute cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes 2021;7:18-
- 11 27.10.1093/ehjqcco/qcaa084
- 12 25. Gadella A, Sastre MÁ, Maicas C, Rodríguez-Padial L, Arias MÁ. ST-segment elevation myocardial infarction in times of
- 13 COVID-19: back to the last century? A call for attention. Rev Esp Cardiol (Engl Ed) 2020;73:582-
- 14 583.10.1016/j.rec.2020.04.009
- 15 26. Moroni F, Gramegna M, Ajello S et al. Collateral Damage: Medical Care Avoidance Behavior Among Patients With
- 16 Myocardial Infarction During the COVID-19 Pandemic. JACC Case Rep 2020;2:1620-1624.10.1016/j.jaccas.2020.04.010
- 17 27. De Rosa S, Spaccarotella C, Basso C et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-
- 18 19 era. Eur Heart J 2020;41:2083-2088.10.1093/eurheartj/ehaa409
- 19 28. Cho KH, Han X, Ahn JH et al. Long-Term Outcomes of Patients With Late Presentation of ST-Segment Elevation
- 20 Myocardial Infarction. J Am Coll Cardiol 2021;77:1859-1870.10.1016/j.jacc.2021.02.041
- 21 29. Munn Z, Peters MDJ, Stern C, Tufanaru C, McArthur A, Aromataris E. Systematic review or scoping review? Guidance
- 22 for authors when choosing between a systematic or scoping review approach. BMC medical research methodology
- 23 2018;18:143.
- 24 https://www.ncbi.nlm.nih.gov/pubmed/30453902 10.1186/s12874-018-0611-x
- 25 30. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. International journal of social research
- 26 *methodology* 2005;8:19-32.
- 27 http://www.tandfonline.com/doi/abs/10.1080/1364557032000119616 10.1080/1364557032000119616

- 1 31. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implementation science : IS
- 2 2010;5:69.
- 3 <u>https://www.ncbi.nlm.nih.gov/pubmed/20854677</u> 10.1186/1748-5908-5-69
- 4 32. Tricco AC, Lillie E, Zarin W et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.
- 5 Annals of internal medicine 2018;169:467-473.10.7326/M18-0850
- 6 33. Alba A, Frankfurter C, Buchan T et al. REDUCED RATE OF HOSPITAL PRESENTATIONS FOR HEART FAILURE
- 7 DURING THE COVID-19 PANDEMIC IN TORONTO, CANADA. Can J Cardiol 2020;36:S74.
- 8 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7529371/ 10.1016/j.cjca.2020.07.147
- 9 34. Araiza-Garaygordobil D, Montalto C, Martinez-Amezcua P et al. Impact of the COVID-19 Pandemic on Hospitalizations
- 10 for Acute Coronary Syndromes: a Multinational Study. *QJM* 2021;10.1093/qjmed/hcab013
- 11 35. Ball S, Banerjee A, Berry C et al. Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular
- 12 diseases in the UK. *Heart* 2020;106:1890-1897.10.1136/heartjnl-2020-317870
- 13 36. Bhatt AS, Moscone A, McElrath EE et al. Fewer Hospitalizations for Acute Cardiovascular Conditions During the
- 14 COVID-19 Pandemic. J Am Coll Cardiol 2020;76:280-288.10.1016/j.jacc.2020.05.038
- 15 37. Boeddinghaus J, Nestelberger T, Kaiser C et al. Effect of COVID-19 on acute treatment of ST-segment elevation and
- 16 Non-ST-segment elevation acute coronary syndrome in northwestern Switzerland. Int J Cardiol Heart Vasc
- 17 2021;32:100686.10.1016/j.ijcha.2020.100686
- 18 38. Bollmann A, Hohenstein S, König S, Meier-Hellmann A, Kuhlen R, Hindricks G. In-hospital mortality in heart failure in
- 19 Germany during the Covid-19 pandemic. *ESC Heart Failure* 2020;7:4416-4419.
- 20 https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.13011 10.1002/ehf2.13011
- 21 39. Bromage DI, Cannatà A, Rind IA et al. The impact of COVID-19 on heart failure hospitalization and management: report
- 22 from a Heart Failure Unit in London during the peak of the pandemic. *European Journal of Heart Failure* 2020;22:978-984.
- 23 <u>https://onlinelibrary.wiley.com/doi/abs/10.1002/ejhf.1925</u> 10.1002/ejhf.1925
- 24 40. Bruoha S, Yosefy C, Gallego-Colon E et al. Impact in total ischemic time and ST-segment elevation myocardial
- 25 infarction admissions during COVID-19. Am J Emerg Med 2021;45:7-10.10.1016/j.ajem.2021.02.020
- 26 41. Bugger H, Gollmer J, Pregartner G et al. Complications and mortality of cardiovascular emergency admissions during
- 27 COVID-19 associated restrictive measures. PLoS One 2020;15:e0239801.10.1371/journal.pone.0239801

- 1 42. Butt JH, Fosbøl EL, Gerds TA et al. All-cause mortality and location of death in patients with established cardiovascular
- 2 disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study. European Heart Journal
- 3 2021;42:1516-1523.
- 4 <u>https://doi.org/10.1093/eurheartj/ehab028</u> 10.1093/eurheartj/ehab028
- 5 43. Claeys MJ, Argacha J, Collart P et al. Impact of COVID-19-related public containment measures on the ST elevation
- 6 myocardial infarction epidemic in Belgium: a nationwide, serial, cross-sectional study. Acta Cardiol 2020;:1-
- 7 7.10.1080/00015385.2020.1796035
- 8 44. Colivicchi F, Di Fusco SA, Magnanti M, Cipriani M, Imperoli G. The Impact of the Coronavirus Disease-2019 Pandemic
- 9 and Italian Lockdown Measures on Clinical Presentation and Management of Acute Heart Failure. J Card Fail 2020;26:464-
- 10 465.
- 11 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7224656/ 10.1016/j.cardfail.2020.05.007
- 12 45. De Filippo O, D'Ascenzo F, Angelini F et al. Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak
- 13 in Northern Italy. N Engl J Med 2020;383:88-89.10.1056/NEJMc2009166
- 14 46. Doolub G, Wong C, Hewitson L et al. Impact of COVID-19 on inpatient referral of acute heart failure: a single-centre
- 15 experience from the south-west of the UK. ESC Heart Failure 2021;8:1691-1695.
- 16 https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.13158 10.1002/ehf2.13158
- 17 47. Erol MK, Kayıkçıoğlu M, Kılıçkap M et al. Treatment delays and in-hospital outcomes in acute myocardial infarction
- 18 during the COVID-19 pandemic: A nationwide study. Anatol J Cardiol 2020;24:334-
- 19 342.10.14744/AnatolJCardiol.2020.98607
- 20 48. Fabris E, Bessi R, De Bellis A et al. COVID-19 impact on ST-elevation myocardial infarction incidence rate in a Italian
- 21 STEMI network: a U-shaped curve phenomenon. Journal of Cardiovascular Medicine 2021;22:344–349.
- 22 https://journals.lww.com/jcardiovascularmedicine/Fulltext/2021/05000/COVID_19_impact_on_ST_elevation_myocardial.3.a
- 23 <u>spx</u> 10.2459/JCM.00000000001153
- 24 49. Fersia O, Bryant S, Nicholson R et al. The impact of the COVID-19 pandemic on cardiology services. Open Heart
- 25 2020;710.1136/openhrt-2020-001359
- 26 50. Fileti L, Vecchio S, Moretti C et al. Impact of the COVID-19 pandemic on coronary invasive procedures at two Italian
- high-volume referral centers. J Cardiovasc Med (Hagerstown) 2020;21:869-873.10.2459/JCM.00000000001101

- 1 51. Folino AF, Zorzi A, Cernetti C et al. Impact of COVID-19 epidemic on coronary care unit accesses for acute coronary
- 2 syndrome in Veneto region, Italy. *Am Heart J* 2020;226:26-28.
- 3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201234/ 10.1016/j.ahj.2020.04.021
- 4 52. Gasior M, Gierlotka M, Tycińska A et al. Effects of the coronavirus disease 2019 pandemic on the number of
- 5 hospitalizations for myocardial infarction: regional differences. Population analysis of 7 million people. *Kardiol Pol*
- 6 2020;78:1039-1042.10.33963/KP.15559
- 7 53. Gitt AK, Karcher AK, Zahn R, Zeymer U. Collateral damage of COVID-19-lockdown in Germany: decline of NSTE-
- 8 ACS admissions. *Clin Res Cardiol* 2020;:1-3.
- 9 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351542/</u> 10.1007/s00392-020-01705-x
- 10 54. Gluckman TJ, Wilson MA, Chiu S et al. Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial
- 11 Infarction During the Coronavirus Disease 2019 Pandemic. JAMA Cardiol 2020;5:1419-1424.10.1001/jamacardio.2020.3629
- 12 55. Gramegna M, Baldetti L, Beneduce A et al. ST-Segment-Elevation Myocardial Infarction During COVID-19 Pandemic:
- 13 Insights From a Regional Public Service Healthcare Hub. *Circ Cardiovasc Interv*
- 14 2020;13:e009413.10.1161/CIRCINTERVENTIONS.120.009413
- 15 56. Holy EW, Jakob P, Manka R et al. Impact of a nationwide COVID-19 lockdown on acute coronary syndrome referrals.
- 16 *Cardiol J* 2020;27:633-635.
- 17 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078978/</u> 10.5603/CJ.a2020.0091
- 18 57. Kapelios CJ, Siafarikas C, Bonou M, Liatis S, Barbetseas J. The effect of the COVID-19 pandemic on acute coronary
- 19 syndrome hospitalizations and out-of-hospital cardiac arrest in Greece. *Public Health* 2021;191:17-
- 20 19.10.1016/j.puhe.2020.12.006
- 21 58. Khalil E, Ozcan S. Comparison of the number of cardiovascular admissions before and after covid-19: Experience from
- 22 Turkey. Acta Medica Mediterranea 2020;:2433-2437.
- 23 <u>https://doi.org/10.19193/0393-6384_2020_4_378</u>
- 24 59. König S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A. In-hospital care in acute heart failure
- during the COVID-19 pandemic: insights from the German-wide Helios hospital network. Eur J Heart Fail 2020;22:2190-
- 26 2201.10.1002/ejhf.2044
- 27 60. König S, Ueberham L, Pellissier V et al. Hospitalization deficit of in- and outpatient cases with cardiovascular diseases
- 28 and utilization of cardiological interventions during the COVID-19 pandemic: Insights from the German-wide helios hospital

- 1 network. *Clinical cardiology* 2021;44:392-400.
- 2 https://onlinelibrary.wiley.com/doi/abs/10.1002/clc.23549 10.1002/clc.23549
- 3 61. Mafham MM, Spata E, Goldacre R et al. COVID-19 pandemic and admission rates for and management of acute
- 4 coronary syndromes in England. *The Lancet* 2020;396:381-389.
- 5 <u>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31356-8/abstract</u> 10.1016/S0140-6736(20)31356-8
- 6 62. MCILVENNAN CK, ALLEN LA, DEVORE AD, GRANGER CB, KALTENBACH LA, GRANGER BB. Changes in
- 7 Care Delivery for Patients With Heart Failure During the COVID-19 Pandemic: Results of a Multicenter Survey. J Card Fail
- 8 2020;26:635-636.
- 9 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272147/</u> 10.1016/j.cardfail.2020.05.019
- 10 63. Moreno R, Alonso JJ, Caballero R et al. Age and Gender influence on time of arrival for STEMI patients during Covid-
- 11 19 pandemic. Am J Emerg Med 2021;42:244-245.
- 12 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274966/ 10.1016/j.ajem.2020.06.013
- 13 64. Nef HM, Elsässer A, Möllmann H et al. Impact of the COVID-19 pandemic on cardiovascular mortality and catherization
- 14 activity during the lockdown in central Germany: an observational study. *Clin Res Cardiol* 2021;110:292-
- 15 301.10.1007/s00392-020-01780-0
- 16 65. Negreira Caamaño M, Piqueras Flores J, Mateo Gómez C. Impact of COVID-19 pandemic in cardiology admissions. *Med*
- 17 *Clin (Engl Ed)* 2020;155:179-180.
- 18 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381901/ 10.1016/j.medcle.2020.05.006
- 19 66. Papafaklis MI, Katsouras CS, Tsigkas G et al. "Missing" acute coronary syndrome hospitalizations during the COVID-19
- 20 era in Greece: Medical care avoidance combined with a true reduction in incidence? *Clin Cardiol* 2020;43:1142-
- 21 1149.10.1002/clc.23424
- 22 67. Pinto RD, Ferri C, Mammarella L et al. Increased cardiovascular death rates in a COVID-19 low prevalence area. The
- 23 Journal of Clinical Hypertension 2020;22:1932-1935.
- 24 <u>https://onlinelibrary.wiley.com/doi/abs/10.1111/jch.14013</u> 10.1111/jch.14013
- 25 68. Primessnig U, Pieske BM, Sherif M. Increased mortality and worse cardiac outcome of acute myocardial infarction
- during the early COVID-19 pandemic. *ESC Heart Failure* 2021;8:333-343.
- 27 <u>https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.13075</u> 10.1002/ehf2.13075

- 1 69. Rattka M, Baumhardt M, Dreyhaupt J et al. 31 days of COVID-19-cardiac events during restriction of public life-a
- 2 comparative study. *Clinical research in cardiology* 2020;109:1476-1482.
- 3 <u>https://www.ncbi.nlm.nih.gov/pubmed/32494921</u> 10.1007/s00392-020-01681-2
- 4 70. Reinstadler SJ, Reindl M, Lechner I et al. Effect of the COVID-19 Pandemic on Treatment Delays in Patients with ST-
- 5 Segment Elevation Myocardial Infarction. J Clin Med 2020;9
- 6 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408681/</u> 10.3390/jcm9072183
- 7 71. Roffi M, Capodanno D, Windecker S, Baumbach A, Dudek D. Impact of the COVID-19 pandemic on interventional
- 8 cardiology practice: results of the EAPCI survey. *EuroIntervention* 2020;16:247-250.10.4244/EIJ-D-20-00528
- 9 72. Schnaubelt S, Domanovits H, Niederdoeckl J et al. The Impact of the COVID-19 Pandemic on Incidences of Atrial
- 10 Fibrillation and Electrical Cardioversion at a Tertiary Care Emergency Department: An Inter- and Intra-year Analysis. Front
- 11 Med (Lausanne) 2020;7:595881.10.3389/fmed.2020.595881
- 12 73. Secco GG, Zocchi C, Parisi R et al. Decrease and Delay in Hospitalization for Acute Coronary Syndromes During the
- 13 2020 SARS-CoV-2 Pandemic. Canadian Journal of Cardiology 2020;36:1152-1155.
- 14 https://www.sciencedirect.com/science/article/pii/S0828282X2030502X 10.1016/j.cjca.2020.05.023
- 15 74. Singh S, Fong HK, Desai R, Zwinderman AH. Impact of COVID-19 on acute coronary syndrome-related
- 16 hospitalizations: A pooled analysis. Int J Cardiol Heart Vasc 2021;32
- 17 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836359/ 10.1016/j.ijcha.2021.100718
- 18 75. Sokolski M, Gajewski P, Zymliński R et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute
- 19 Admissions at the Emergency and Cardiology Departments Across Europe. Am J Med 2021;134:482-
- 20 489.10.1016/j.amjmed.2020.08.043
- 21 76. Solomon MD, McNulty EJ, Rana JS et al. The Covid-19 Pandemic and the Incidence of Acute Myocardial Infarction. N
- 22 Engl J Med 2020;383:691-693.10.1056/NEJMc2015630
- 23 77. Tomasoni D, Adamo M, Italia L et al. Impact of COVID-2019 outbreak on prevalence, clinical presentation and
- 24 outcomes of ST-elevation myocardial infarction. J Cardiovasc Med (Hagerstown) 2020;21:874-
- 25 881.10.2459/JCM.000000000001098
- 26 78. Vassilikos VP, Pagourelias ED, Katsos K et al. Impact of social containment measures on cardiovascular admissions and
- 27 sudden cardiac death rates during Coronavirus Disease (COVID-19) outbreak in Greece. *Hellenic J Cardiol* 2020;
- 28 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491429/ 10.1016/j.hjc.2020.09.009

- 1 79. Vecchio S, Fileti L, Reggi A, Moschini C, Lorenzetti S, Rubboli A. Impact of the COVID-19 pandemic on admissions for
- 2 acute coronary syndrome: review of the literature and single-center experience. G Ital Cardiol (Rome) 2020;21:502-
- 3 508.10.1714/3386.33635
- 4 80. Vest AR, Upshaw JN, Dean K et al. The Decrease in Hospitalizations For Heart Failure During the Covid-19 Pandemic:
- 5 A Community and Academic Hospital Comparison Study. J Card Fail 2020;26:S71.
- 6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527197/ 10.1016/j.cardfail.2020.09.207
- 7 81. Wu J, Mamas M, Rashid M et al. Patient response, treatments, and mortality for acute myocardial infarction during the
- 8 COVID-19 pandemic. European Heart Journal Quality of Care and Clinical Outcomes 2021;7:238-246.
- 9 https://doi.org/10.1093/ehjqcco/qcaa062 10.1093/ehjqcco/qcaa062
- 10 82. Aldujeli A, Hamadeh A, Briedis K et al. Delays in Presentation in Patients With Acute Myocardial Infarction During the
- 11 COVID-19 Pandemic. Cardiol Res 2020;11:386-391.10.14740/cr1175
- 12 83. Hammad TA, Parikh M, Tashtish N et al. Impact of COVID-19 pandemic on ST-elevation myocardial infarction in a
- 13 non-COVID-19 epicenter. Catheter Cardiovasc Interv 2021;97:208-214.10.1002/ccd.28997
- 14 84. Kitahara S, Fujino M, Honda S et al. COVID-19 pandemic is associated with mechanical complications in patients with
- 15 ST-elevation myocardial infarction. Open Heart 2021;810.1136/openhrt-2020-001497
- 16 85. Perrin N, Iglesias JF, Rey F et al. Impact of the COVID-19 pandemic on acute coronary syndromes. *Swiss Med Wkly*
- 17 2020;150:w20448.10.4414/smw.2020.20448
- 18 86. Toner L, Koshy AN, Hamilton GW, Clark D, Farouque O, Yudi MB. Acute coronary syndromes undergoing
- 19 percutaneous coronary intervention in the COVID-19 era: comparable case volumes but delayed symptom onset to hospital
- 20 presentation. Eur Heart J Qual Care Clin Outcomes 2020;6:225-226.10.1093/ehjqcco/qcaa038
- 21 87. Wilson SJ, Connolly MJ, Elghamry Z et al. Effect of the COVID-19 Pandemic on ST-Segment-Elevation Myocardial
- 22 Infarction Presentations and In-Hospital Outcomes. Circ Cardiovasc Interv
- 23 2020;13:e009438.10.1161/CIRCINTERVENTIONS.120.009438
- 24 88. Yong CM, Ang L, Welt FGP et al. Cardiac procedural deferral during the coronavirus (COVID-19) pandemic. *Catheter*
- 25 Cardiovasc Interv 2020;96:1080-1086.10.1002/ccd.29262

- 1 89. Barbieri L, Tumminello G, Lucreziotti S et al. Mortality in STEMI Patients During the COVID Era: Has the Pandemic
- 2 Changed Our Clinical Practice? *Cardiovasc Revasc Med* 2021;22:120-121.
- 3 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488593/</u> 10.1016/j.carrev.2020.09.014
- 4 90. Chen Y, Rathod KS, Hamshere S et al. COVID-19 and changes in activity and treatment of ST elevation MI from a UK
- 5 cardiac centre. Int J Cardiol Heart Vasc 2021;33:100736.10.1016/j.ijcha.2021.100736
- 6 91. De Luca G, Cercek M, Jensen LO et al. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in
- 7 patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovasc Diabetol
- 8 2020;19:215.10.1186/s12933-020-01196-0
- 9 92. De Rosa S, Spaccarotella C, Basso C et al. Reduction of hospitalizations for myocardial infarction in Italy in the COVID-
- 10 19 era. Eur Heart J 2020;41:2083-2088.10.1093/eurheartj/ehaa409
- 11 93. Haddad K, Potter BJ, Matteau A, Gobeil F, Mansour S. Implications of COVID-19 on Time-Sensitive STEMI Care: A
- 12 Report From a North American Epicenter. Cardiovasc Revasc Med 2021;30:33-37.10.1016/j.carrev.2020.09.024
- 13 94. Hannan EL, Wu Y, Cozzens K et al. Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction Before
- 14 and During COVID in New York. Am J Cardiol 2021;142:25-34.10.1016/j.amjcard.2020.11.033
- 15 95. Hauguel-Moreau M, Pillière R, Prati G et al. Impact of Coronavirus Disease 2019 outbreak on acute coronary syndrome
- 16 admissions: four weeks to reverse the trend. J Thromb Thrombolysis 2020;:1-2.
- 17 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323878/ 10.1007/s11239-020-02201-9
- 18 96. Kobo O, Efraim R, Saada M et al. The impact of lockdown enforcement during the SARSCoV-2 pandemic on the timing
- 19 of presentation and early outcomes of patients with ST-elevation myocardial infarction. *PLoS One*
- 20 2020;15:e0241149.10.1371/journal.pone.0241149
- 21 97. Kwok CS, Gale CP, Kinnaird T et al. Impact of COVID-19 on percutaneous coronary intervention for ST-elevation
- 22 myocardial infarction. Heart 2020;106:1805-1811.10.1136/heartjnl-2020-317650
- 23 98. Little CD, Kotecha T, Candilio L et al. COVID-19 pandemic and STEMI: pathway activation and outcomes from the
- 24 pan-London heart attack group. Open Heart 2020;710.1136/openhrt-2020-001432
- 25 99. Nader J, Anselmi A, Tomasi J et al. Adult cardiac surgery during COVID-19 lockdown: Impact on activity and outcomes
- 26 in a high-volume centre. Arch Cardiovasc Dis 2021;114:364-370.10.1016/j.acvd.2020.12.003

- 1 100. Pascual Calleja I, Álvarez Velasco R, Almendarez Lacayo M, Arboine Aguirre L, Avanzas Fernández P, Moris de la
- 2 Tassa, César. Impact of the COVID-19 pandemic on acute myocardial infarction care times. *Emergencias* 2020;32:440-442.
- 3 101. Popovic B, Varlot J, Metzdorf PA, Jeulin H, Goehringer F, Camenzind E. Changes in characteristics and management
- 4 among patients with ST-elevation myocardial infarction due to COVID-19 infection. Catheter Cardiovasc Interv
- 5 2021;97:E319-E326.10.1002/ccd.29114
- 6 102. Rodríguez-Leor O, Cid-Álvarez B, Pérez de Prado A et al. Impact of COVID-19 on ST-segment elevation myocardial
- 7 infarction care. The Spanish experience. *Rev Esp Cardiol (Engl Ed)* 2020;73:994-1002.10.1016/j.rec.2020.08.002
- 8 103. Scholz KH, Lengenfelder B, Thilo C et al. Impact of COVID-19 outbreak on regional STEMI care in Germany. *Clin*
- 9 Res Cardiol 2020;109:1511-1521.10.1007/s00392-020-01703-z
- 10 104. Garcia S, Stanberry L, Schmidt C et al. Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the
- 11 United States. Catheter Cardiovasc Interv 2021;98:217-222.10.1002/ccd.29154
- 12 105. Nappi C, Megna R, Acampa W et al. Effects of the COVID-19 pandemic on myocardial perfusion imaging for ischemic
- 13 heart disease. *Eur J Nucl Med Mol Imaging* 2020;:1-7.
- 14 <u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417201/</u> 10.1007/s00259-020-04994-6
- 15 106. Quadri G, Rognoni A, Cerrato E et al. Catheterization laboratory activity before and during COVID-19 spread: A
- 16 comparative analysis in Piedmont, Italy, by the Italian Society of Interventional Cardiology (GISE). Int J Cardiol
- 17 2021;323:288-291.10.1016/j.ijcard.2020.08.072
- 18 107. Casey L, Khan N, Healy DG. The impact of the COVID-19 pandemic on cardiac surgery and transplant services in
- 19 Ireland's National Centre. Ir J Med Sci 2020;:1-5.
- 20 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7335226/ 10.1007/s11845-020-02292-6
- 21 108. Elliott JM, Crozier IG. Decreases in cardiac catheter laboratory workload during the COVID-19 level 4 lockdown in
- 22 New Zealand. Intern Med J 2020;50:1000-1003.10.1111/imj.14922
- 23 109. Iafrancesco M, Farina P, Bruno P et al. Impact of Covid-19 Pandemia on Provision of Surgical Treatment for Patients
- 24 With Cardiovascular Disease. *Circulation* 2020;142:A15347-A15347.
- 25 <u>https://www.ahajournals.org/doi/abs/10.1161/circ.142.suppl_3.15347</u> 10.1161/circ.142.suppl_3.15347

- 1 110. Ishii H, Amano T, Yamaji K, Kohsaka S, Yokoi H, Ikari Y. Implementation of Percutaneous Coronary Intervention
- 2 During the COVID-19 Pandemic in Japan Nationwide Survey Report of the Japanese Association of Cardiovascular
- 3 Intervention and Therapeutics for Cardiovascular Disease. Circ J 2020;84:2185-2189.10.1253/circj.CJ-20-0708
- 4 111. Kwok CS, Gale CP, Curzen N et al. Impact of the COVID-19 Pandemic on Percutaneous Coronary Intervention in
- 5 England: Insights From the British Cardiovascular Intervention Society PCI Database Cohort. Circ Cardiovasc Interv
- 6 2020;13:e009654.10.1161/CIRCINTERVENTIONS.120.009654
- 7 112. Mohamed MO, Kinnaird T, Curzen N et al. In-Hospital and 30-Day Mortality After Percutaneous Coronary Intervention
- 8 in England in the Pre-COVID and COVID Eras. *J Invasive Cardiol* 2021;33:E206-E219.
- 9 113. Rodríguez-Caulo EA, Carnero Alcázar M, Garrido Jiménez JM, Barquero Aroca JM. National survey: Impact of
- 10 COVID-19 on cardiovascular surgery services in Spain (SECCE-COVID19 Study. Cirugía Cardiovascular 2021;28:67-70.
- 11 https://www.sciencedirect.com/science/article/pii/S1134009621000164 10.1016/j.circv.2021.01.003
- 12 114. Soylu K, Coksevim M, Yanik A, Bugra Cerik I, Aksan G. Effect of Covid-19 pandemic process on STEMI patients
- 13 timeline. Int J Clin Pract 2021;75:e14005.10.1111/ijcp.14005
- 14 115. Rebollal-Leal F, Aldama-López G, Flores-Ríos X et al. Impact of COVID-19 outbreak and public lockdown on ST-
- 15 segment elevation myocardial infarction care in Spain. Cardiol J 2020;27:425-426.10.5603/CJ.a2020.0098
- 16 116. Einstein AJ, Shaw LJ, Hirschfeld C et al. International Impact of COVID-19 on the Diagnosis of Heart Disease. J Am
- 17 Coll Cardiol 2021;77:173-185.10.1016/j.jacc.2020.10.054
- 18 117. European Society of Hypertension Corona-virus Disease 19 Task Force. The corona-virus disease 2019 pandemic
- 19 compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of
- 20 Hypertension. J Hypertens 2021;39:190-195.10.1097/HJH.000000000002703
- 21 118. Sankaranarayanan R, Hartshorne-Evans N, Redmond-Lyon S et al. The impact of COVID-19 on the management of
- heart failure: a United Kingdom patient questionnaire study. ESC Heart Fail 2021;8:1324-1332.10.1002/ehf2.13209
- 23 119. Wosik J, Clowse MEB, Overton R et al. Impact of the COVID-19 pandemic on patterns of outpatient cardiovascular
- 24 care. Am Heart J 2021;231:1-5.10.1016/j.ahj.2020.10.074
- 25 120. Chagué F, Boulin M, Eicher J et al. Impact of lockdown on patients with congestive heart failure during the coronavirus
- disease 2019 pandemic. ESC Heart Fail 2020;10.1002/ehf2.13016

- 1 121. Wadhera RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular Deaths During the COVID-19 Pandemic in
- 2 the United States. J Am Coll Cardiol 2021;77:159-169.10.1016/j.jacc.2020.10.055
- 3 122. Czeisler MÉ. Delay or Avoidance of Medical Care Because of COVID-19–Related Concerns United States, June
- 4 2020. MMWR Morb Mortal Wkly Rep 2020;69
- 5 <u>https://www.cdc.gov/mmwr/volumes/69/wr/mm6936a4.htm</u> 10.15585/mmwr.mm6936a4
- 6 123. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons
- 7 learned from air pollution. *Nat Rev Cardiol* 2020;17:656-672.
- 8 <u>https://www.nature.com/articles/s41569-020-0371-2</u> 10.1038/s41569-020-0371-2
- 9 124. Venter ZS, Aunan K, Chowdhury S, Lelieveld J. COVID-19 lockdowns cause global air pollution declines. Proc Natl
- 10 Acad Sci U S A 2020;117:18984-18990.10.1073/pnas.2006853117
- 11 125. Krumholz M.D. HM. Where Have All the Heart Attacks Gone? *The New York Times* 2020;
- 12 https://www.nytimes.com/2020/04/06/well/live/coronavirus-doctors-hospitals-emergency-care-heart-attack-
- 13 stroke.html
- 14 126. Coronavirus doctor's diary: Is lockdown good for your heart? *BBC News* 2020;
- 15 https://www.bbc.com/news/health-52535044
- 16 127. Harky A, Harrington D, Nawaytou O et al. COVID-19 and cardiac surgery: The perspective from United Kingdom. J
- 17 Card Surg 2020;
- 18 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537188/ 10.1111/jocs.15039
- 19 128. The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the
- 20 COVID-19 Pandemic.
- 21 https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance,
- 22 https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance (13-10-2021)
- 23 129. HealthPros network.
- 24 <u>https://www.healthpros-h2020.eu/index.php/output</u> (23-08-2021)
- 25 130. Kringos D, Carinci F, Barbazza E et al. Managing COVID-19 within and across health systems: why we need
- 26 performance intelligence to coordinate a global response. *Health Res Policy Syst* 2020;18:80.10.1186/s12961-020-00593-x